Prokidney (PROK) Cash from Operations (2021 - 2026)
Prokidney's (PROK) quarterly Cash from Operations came in at -$40.4 million in Q2 2026, down 28.51% year-over-year from -$56.5 million in Q2 2025, and up 3.14% quarter-over-quarter from -$41.7 million in Q1 2026.
Analysis
Prokidney (PROK) Cash from Operations (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Cash from Operations for 6 consecutive years, with -$40.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Operations fell 28.51% year-over-year to -$40.4 million in Q2 2026; TTM through Jun 2026 was -$141.2 million, a 23.38% decrease from a year earlier, with the FY2025 full-year figure at -$120.1 million, up 4.93% from the prior year.
- Cash from Operations was -$40.4 million for Q2 2026 at Prokidney, up from -$41.7 million in the prior quarter.
- Over five years, Cash from Operations peaked at -$14.9 million in Q2 2023 and troughed at -$41.7 million in Q1 2026.
- A 5-year average of -$27.5 million and a median of -$26.3 million in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 11202073.91% in 2022 and surged 35.22% in 2023, its largest moves.
- Over 5 years, Cash from Operations stood at -$15.8 million in 2022, then tumbled by 61.06% to -$25.4 million in 2023, then advanced by 4.78% to -$24.2 million in 2024, then plunged by 34.51% to -$32.5 million in 2025, then decreased by 24.18% to -$40.4 million in 2026.
- The last three Cash from Operations figures came in at -$40.4 million (Q2 2026), -$41.7 million (Q1 2026), and -$32.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 74.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -83.50 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -60.82 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -20.90 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -28.58 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -66.10 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | -17.81 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 197.07 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 16.19 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | -40.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -40.37 Mn |
| Mar 31, 2026 | -41.68 Mn |
| Dec 31, 2025 | -32.51 Mn |
| Sep 30, 2025 | -26.60 Mn |
| Jun 30, 2025 | -31.42 Mn |
| Mar 31, 2025 | -29.59 Mn |
| Dec 31, 2024 | -24.17 Mn |
| Sep 30, 2024 | -29.24 Mn |
| Jun 30, 2024 | -38.29 Mn |
| Mar 31, 2024 | -34.65 Mn |
| Dec 31, 2023 | -25.38 Mn |
| Sep 30, 2023 | -23.78 Mn |
| Jun 30, 2023 | -14.92 Mn |
| Mar 31, 2023 | -25.99 Mn |
| Dec 31, 2022 | -15.76 Mn |
| Sep 30, 2022 | -22.84 Mn |
| Jun 30, 2022 | -23.03 Mn |
| Mar 31, 2022 | -15.46 Mn |
| Dec 31, 2021 | -1.21 Mn |
| Sep 30, 2021 | -1.14 Mn |